KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ability to treat corneal persistent epithelial defects (PEDs) or corneal ...

Shares of Krystal Biotech KRYS gained 3.9% yesterday after the company announced that it had dosed the first patient in a ...

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

Loss of corneal epithelium ... The epithelial defect gradually healed during the following month. When he was last examined, on January 18, 1966, vision in the left eye was 20/15.

A 68-year-old insulin-dependent diabetic male patient presented with progressive pain, redness, photophobia, tearing, and decreased vision of 1-month duration in his left eye. He had history of ...

Amgen (AMGN) announced on Monday that a late-stage study evaluating its Bemarituzumab in combination with chemotherapy met ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and ...